PCVX

Based on Vaxcyte, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Vaxcyte do?

Vaxcyte is a clinical-stage biotechnology company developing protein-based vaccines against serious bacterial infections. Its pipeline targets pneumococcal disease, Group A Streptococcus, and periodontitis using a cell-free protein synthesis platform. The company has no marketed products yet and is advancing its candidates through clinical trials.

Does PCVX pay dividends?

No, Vaxcyte does not pay a dividend. As a pre-revenue clinical-stage company, all capital is reinvested into research and clinical development. Dividend payments are not expected until the company reaches commercial-stage operations, which remains contingent on successful trial outcomes.

When does PCVX report earnings?

Vaxcyte reports on a standard quarterly cadence. Because it is pre-revenue, reports center on cash position, operating spend, and pipeline updates rather than sales figures. Check Vaxcyte's investor relations page for the most current reporting schedule and recent results.

Is PCVX a good stock to buy?

UQS Score rates PCVX as Poor overall, driven by Weak Quality and Growth pillars alongside an Elevated Valuation. The Strong Risk rating is a relative positive, indicating financial runway. Whether it suits an investor depends on their risk tolerance for clinical-stage biotech. View the full pillar breakdown on UQS Pro for a complete picture.

Is PCVX overvalued?

The UQS Valuation pillar for PCVX is rated Elevated, suggesting the current market price reflects optimistic assumptions about pipeline success. For a pre-revenue company, valuation is inherently forward-looking and sensitive to clinical trial outcomes. The complete valuation analysis is available to UQS Pro members.

How does PCVX compare to its competitors?

Compared to peers like Bio-Techne, which generates diversified commercial revenue, Vaxcyte is at an earlier stage with a narrower, vaccine-focused pipeline. Against clinical-stage peers such as Arrowhead Pharmaceuticals, Vaxcyte is differentiated by its bacterial disease focus and cell-free synthesis platform rather than RNA-based approaches.

What is PCVX's market cap bracket?

Vaxcyte is classified as a mid-cap stock. This places it in a range that typically attracts both institutional and retail investor interest, though mid-cap clinical-stage biotechs can carry significant volatility tied to trial readouts and regulatory decisions.

Who founded Vaxcyte?

Vaxcyte was originally incorporated in 2013 under the name SutroVax, Inc. and rebranded as Vaxcyte in May 2020. Founding details and leadership history are publicly available through the company's official filings and investor relations materials.

Is PCVX a long-term quality investment?

As a long-term quality indicator, UQS rates PCVX as Poor at this stage, reflecting its pre-revenue status and Weak Quality and Growth scores. Long-term quality potential hinges on successful clinical advancement and eventual commercialization. The Strong Risk pillar does suggest the company is positioned to sustain operations through key milestones.

What is the main competitive advantage of Vaxcyte?

Vaxcyte's primary differentiator is its cell-free protein synthesis platform, which the company believes enables more precise vaccine engineering than traditional cell-based methods. This technology underpins its ability to design high-valency conjugate vaccines like VAX-24, potentially offering broader protection than existing approved pneumococcal vaccines.

Is PCVX a growth stock or value stock?

Based on UQS pillar labels, PCVX carries a Weak Growth rating and an Elevated Valuation — a combination that fits neither a classic growth nor value profile. It is best characterized as a speculative clinical-stage biotech where the investment case rests on pipeline outcomes rather than current financial performance.

Vaxcyte, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Vaxcyte, Inc. faces growth headwinds with declining or stagnant revenue trends.

Vaxcyte, Inc. maintains a reasonable risk profile with manageable debt levels.

Vaxcyte, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Vaxcyte, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PCVX.

The UQS (Unified Quality Score) for Vaxcyte, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Vaxcyte, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Vaxcyte, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.